Global Short Bowel Syndrome Market - Market Size, Share & Industry Trends, Growth Analysis Report By Drug Type, By Distribution Channel Type, By Region Type and Forecast 2019 - 2025


DescriptionTable of ContentList of TablesList of Figures
Introduction
Short Bowel Syndrome Market was valued at USD XX Billion in 2019 and is projected to reach USD XX billion by 2025, at a CAGR of XX% from 2020-2025. Short Bowel Syndrome is a group of complex diseases that occurs due to malfunction of a portion of small and/or large intestine. Short bowel syndrome can lead to Crohn’s disease, injury or trauma to the small intestine. Such complications are driving the growth of the short bowel syndrome market. Additionally, increasing prescriptions of Gattex and Revestive in U.S. and Europe respectively, increasing demand for growth hormones and glutamine, are also major driving factors for the Short Bowel Syndrome Market.
On the other hand, risks associated with increased blood flow due to splanchnic perfusion after glepaglutide administration, efficacy in extensive preclinical characterization, are some of the restraining factor this Market. 
Geographical Overview
At a global level, the North America region was holding the highest market share in 2019, due to the revenue generated by Gattex, increasing sedentary lifestyle, increased consumption of unhealthy and junk food, causes to intestinal disorders. Europe is leading at the second position after the North America region, due to high R&D activities, rapid approval of drugs. Whereas, Asia Pacific region is considered the fastest-growing region with key players adopting expansion strategy in this region to gain maximum market share in the coming years. Key factors such as changing eating habits, huge patient pool in China and India, uncontrolled consumption of antibiotics in India, investment in R&D, are driving Short Bowel Syndrome Market in the Asia Pacific region.
?
Segmental Overview
Short Bowel Syndrome Market is segmented as per below specifications -  
By Drug Type: 
• GLP-2
• Growth Hormone
• Glutamine
• Others
By Distribution Channel Type: 
• Hospital Pharmacies
• Retail Pharmacies
• Others

Competitor Analysis
Short Bowel Syndrome Market has presence of some of the key major players across globe which includes
• Merck KGaA
• Ardelyx, Inc.
• Emmaus Life Sciences, Inc.
• GLyPharma Therapeutics, Inc.
• Naia Pharmaceuticals, Inc.
• Nutrinia Ltd.
• OxThera
• Shire PLC
• Zealand Pharma A/S
• TAKEDA, Inc.
These key players are concentrating its efforts on the continuous product improvement with innovative initiatives to have an edge over other competitors. Further, to garner maximum market share, companies are adopting merger/ acquisition/ partnership and maintaining strong distribution networks strategies.  

By Geographical Locations: 
• North America
o U.S.
o Canada
• Europe
o U.K.
o France
o Italy
o Germany
o Spain
o Russia & CIS
o Rest of Europe
• Asia-Pacific
o China 
o India
o Japan
o South Korea
o ASEAN
o Rest of Asia Pacific 
• Latin America
o Brazil
o Argentina
o Rest of LATAM
• Middle East & Africa
o UAE
o South Africa
o Rest of MEA
Highlights of the report
What is Short Bowel Syndrome Market?
Who all are key market players in the industry?
How the Parent Industry is growing?
Where are the key opportunities for new market entrant?
A comprehensive analysis, which covers key growth factors across the value chain
Recent developments in market
Granular Market Segmentation 
Market size projection based on Historical & current market trends 
Market share analysis and key strategies adopted by leading players
Production Cost & Sensitivity Analysis
Country Level Market Analysis of Top 16 countries
Data Driven Decision Recommendations